Association of common genetic alterations with tumor recurrence in papillary thyroid cancer

Clicks: 1
ID: 317237
2026
Free PDF
Article Quality & Performance Metrics
Overall Quality
Not rated
Combines reader engagement with the AI quality analysis. This article has not been analysed, so there is no overall score — reader engagement is measured and shown alongside.
AI Quality Assessment
Not analyzed
Readership in this journal

Ranked #304 of 332 articles by views in JNCI Journal of the National Cancer Institute

Most read Least read

Bar heights use a square-root scale. Only the 120 most-read articles are drawn; the journal has 332 in total.

Mint this article as an NFT
Not yet minted

Create a permanent, verifiable on-chain record of this article on the Scimatic Network. The NFT is held in your Journament account, and you can withdraw it to your own wallet at any time.

5 SUSD one-off · no wallet required
Sign in to mint
Abstract
BACKGROUND: To comprehensively investigate the relationship between common genetic alterations and tumor recurrence in patients with papillary thyroid cancer (PTC) and evaluate whether integrating genetic status could improve the performance of the 2025 American Thyroid Association (ATA) tumor recurrence risk stratification system (RSS). METHODS: This retrospective study included 2,056 patients (1,414 females and 642 males) with a median age of 39 years [interquartile range (IQR), 31-50 years] and a median follow-up time of 25 months (IQR, 13-35 months) who were treated for PTC at three medical centers in China between 2020 and 2024. RESULTS: Tumor recurrence rates were significantly higher in patients carrying RET fusions alone or genetic alteration combination, but not in patients carrying BRAF V600E alone, RAS mutations alone, or NTRK fusions alone, than that in patients without any genetic alteration, with an HR of 2.64 (95% CI, 1.31-5.32) and 3.37 (95% CI, 1.21-9.35) after adjusted for clinicopathological factors, respectively. RET fusions or genetic alteration combination were significantly associated with increased risk of tumor recurrence in all the ATA RSS categories, with an adjusted HR of 14.02 (95% CI, 3.75-52.48) in patients with ATA RSS low or low-intermediate categories, an HR of 3.01 (95% CI, 1.51-5.99) in the intermediate-high category, and an HR of 3.75 (95% CI, 2.17-6.48) in the high category, respectively. CONCLUSION: RET fusions and genetic alteration combination are independent prognostic markers for tumor recurrence of PTC, integrating tumors' genetic status into the 2025 ATA RSS system improves the accuracy of risk stratification for PTC.
Reference Key
openalex_W7164671269 Use this key to autocite in the manuscript while using SciMatic Manuscript Manager or Thesis Manager
Authors Shi-Tong Yu, Liyuan Huang, Hui Tang, Ruitian Ouyang, Guobin Miao, Nanfen Zhou, Shujing Mao, Jichun Yu, 刘仍允, Shangtong Lei
Journal JNCI Journal of the National Cancer Institute
Year 2026
DOI
10.1093/jnci/djag190
URL
https://doi.org/10.1093/jnci/djag190
Keywords Keywords not found

Citations

No citations found. To add a citation, contact the admin at info@scimatic.org

Comments

No comments yet. Be the first to comment on this article.